FDA grants priority review for Xtandi in expanded mCRPC use
This article was originally published in Scrip
Executive Summary
The FDA has granted a priority review for Medivation's and Astellas' supplemental new drug application (sNDA) for Xtandi (enzalutamide) to treat men with metastatic castration-resistant prostate cancer (mCRPC) who have not received chemotherapy.